Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® ...

The shot was cleared for the disease known as MASH, or metabolic-associated steatohepatitis, in adults with moderate to ...

Novo Nordisk A/S’s weight-loss drug Wegovy has received FDA approval to treat a serious form of liver disease, giving the ...

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

Decision makes Wegovy the first GLP-1 class therapy cleared for MASH, a liver condition that affects around 5 per cent of ...

The new approval allows the GLP-1 to be used to treat adults with the liver disease metabolic dysfunction-associated steatohepatitis (MASH) and liver scarring. Wegovy is the first GLP-1 to receive ...

The move follows a Trump administration push to reduce drug prices in America (or, at least, effectively level them across the world). In late July, the president sent letters to the CEOs of top U.S.

MAKERS of the fat jab Wegovy say they will not increase the price of the drug when the cost of rival Mounjaro doubles next ...

Celeste Ntuli opened up on her battle with obesity. The star's comments comes as Mzansi is discussing the new looks of celebs ...